Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.
about
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patientsCan the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-AnalysisPretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-AnalysisPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisTumor macroenvironment and metabolism.Neutrophil to lymphocyte ratio predicts persistent organ failure and in-hospital mortality in an Asian Chinese population of acute pancreatitis.Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis.Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma.Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma.C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection.Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma.Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma.Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiationExternal validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.Evaluation of the association of sleep apnea-related systemic inflammation with CRP, ESR, and neutrophil-to-lymphocyte ratio.Prognostic role of NLR in urinary cancers: a meta-analysisPrognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic reviewThe neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysisTrial Watch: Therapeutic vaccines in metastatic renal cell carcinomaNeutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic ActivityPrognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic FactorPretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma.Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung CancerSystemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma.Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy.Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals.Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma.Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular CarcinomaPrognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram.The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma.Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patientsPeripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte.Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinomaClinical Significance of Preoperative Neutrophil - to - Lymphocyte Ratio in Renal Cell Carcinoma.
P2860
Q24568136-A17278A8-FC8F-4A36-88E0-770A38D3A07CQ26765926-60CB9BA1-AEFA-4B7B-B9ED-8765CBB9FA84Q26786160-2303306D-3EC4-4FEB-B445-E7CBB70474C4Q27022482-AFA77323-938E-49FA-B582-CFC281C097EBQ33574461-91317D36-4B53-4284-963F-1F668AAF6784Q33595219-98E977E9-DE79-4AEC-881A-F87F15763A6AQ33613637-943DF3A9-E55B-48F2-80F9-AF3D0C8F6406Q33652003-779C595A-6B34-4996-B806-7F11D6347498Q33684941-4C386B75-2D4F-4165-B6CA-495C671BB663Q33792392-19742802-50AA-4AD0-9B9F-5964D18CA06DQ33877471-59AF08E4-2953-4013-80B2-FDB240261359Q33912315-2BA7C58D-E5BB-476E-A713-3E1D972F5197Q34793982-39E559D9-C309-41A2-98D5-4245525B3F5CQ34902619-9434AA24-2AE6-435F-A255-C83A69907360Q34989484-9FD6259C-7496-4FED-ABFC-D5AA02FD971CQ35040836-C1A5CC74-EFC3-4605-AA8A-AD62EAD8F5F9Q35105057-907486E8-F5CA-41FE-BC76-44808D65EA50Q35124106-DE1B0365-3609-4223-8128-54B587EB6E8DQ35202177-4AD1CBAD-A484-4ABF-A337-73ECFC6E86A2Q35274955-65E6DF3B-74C5-4EF4-AB45-C3D3B6A8E7D8Q35332425-E8B5C61D-1A45-460E-BD73-2D10E3D2C5D5Q35799377-D9D51C42-6059-4C34-BE15-4A7C1FDDD4B6Q35881343-DDD7E74C-3F1D-440D-B775-A7A09194779FQ35884149-5EEC3FF7-2624-42BE-AEAA-609F4C0BEC0FQ35984951-ACB87CAD-7A3F-49B0-92C1-72323F3BB469Q36023202-390D1D1E-EE93-4419-B3F9-754AF1A10F0BQ36070506-47AD1CD7-1CE2-4E0A-80A4-12CF512BF6E4Q36151154-C0827CEA-9CC7-4C20-B31F-B35E1BE8C239Q36287097-9CCEAFC4-0B51-4C19-8639-399DE37D7629Q36307615-0CFF3FA6-17C1-4057-AECB-B0EC96115FE5Q36326380-FDA9FC33-A53A-4BA3-9AE2-EB3CD9732838Q36464694-2EE550FC-1F28-4714-ADC7-BA008F188C3FQ36567016-03C6B793-B512-472C-B31C-636A0C0F7C8FQ36755754-7606873B-660B-4B6B-B61B-A724FE679760Q36784093-C2622135-FF62-49E2-91D5-E8C6BCFE5542Q37040624-F86503B7-C8CF-4A1E-AC46-394426F8715BQ37040673-188AFE5A-2282-4E6E-A485-8A52A4C825A0Q37175931-84500A6D-B602-42BD-967F-3853ABFDD569Q37214300-7EA4EB80-F9C9-49B6-BC94-743017B229E5Q37221772-6CF179CD-3006-40D8-8452-D9ACCE125EE5
P2860
Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@ast
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@en
type
label
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@ast
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@en
prefLabel
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@ast
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@en
P2093
P2860
P356
P1476
Validation of the pre-treatmen ...... renal cell carcinoma patients.
@en
P2093
C Stoeckigt
G C Hutterer
K Eberhard
R Zigeuner
S Mannweiler
T F Chromecki
P2860
P2888
P304
P356
10.1038/BJC.2013.28
P407
P577
2013-02-05T00:00:00Z